PAR •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization0.000095 mln
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-115
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0.00%
No payout
Business Description
Neovacs S.A. is a French biotechnology company founded in 1993 that develops therapeutic vaccines to treat autoimmune, inflammatory, allergic, and cancer-related conditions. Its core technology, called Kinoid, works by prompting the immune system to produce its own natural antibodies against harmful proteins. The company's lead product, IFNa Kinoid, has advanced through multiple clinical trials for conditions such as lupus, asthma, dermatomyositis, and food allergies, while another vaccine in development targets two proteins linked to allergic disease.
